Author

A. Stähle

Observed names: A STAHLE, A Stähle, A Ståhle, A. Stahle, AK Stähle

Institutions: Philipps University of Marburg, Odense University Hospital, Centre Léon Bérard, University Hospital Ulm, University of Tübingen

Observed institutions: Goethe University Frankfurt, Uppsala University Hospital, Philipps University of Marburg, Universität Innsbruck, Universität Ulm, Odense University Hospital, Christian-Albrechts-Universität zu Kiel, Arbeitsgemeinschaft Gynäkologische Onkologie Studiengruppe, Centre Léon Bérard, University Hospital Schleswig-Holstein, St. Vincentius-Kliniken, Klinikum Bremen-Mitte, University Hospital Ulm, Canadian Cancer Trials Group, University of Tübingen

OpenAlex ID: A5110029590

Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum–taxane based therapy—A phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6)☆

2006 · U WAGNER, A DUBOIS, et al. · Gynecologic Oncology · 89

Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy—a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group

2005 · F. Hilpert, A. Stähle, et al. · Supportive Care in Cancer · 71

Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG

2004 · J. Pfisterer, M. Plante, et al. · Journal of Clinical Oncology · 64

Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: A prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut)

2007 · A. du Bois, J. Pfisterer, et al. · Gynecologic Oncology · 59

Epirubicin/paclitaxel (EP) vs. capecitabine/paclitaxel (XP) in first-line metastatic breast cancer (MBC): A prospective, randomized multicentre phase III study of the AGO breast cancer study group

2006 · H. Lueck, G. V. Minckwitz, et al. · Journal of Clinical Oncology · 25

567 Paclitaxel/Carboplatin (TC) Vs Paclitaxel/Carboplatin Followed By Topotecan (TC-TOP) in First-Line Treatment of Ovarian Cancer Figo Stages IIB–IV. Interim Results of A Gynecologic Cancer Intergroup Phase III Trial of The Ago Ovarian Cancer Study Group and Gineco

2004 · W. Schroder, W. Meier, et al. · International Journal of Gynecological Cancer · 14

A randomized, phase III study (AGO-OVAR-9, GINECO-TCG, NSGO-OC-0102): Gemcitabine-paclitaxel-carboplatin versus paclitaxel-carboplatin as first-line treatment of ovarian cancer (OC): Survival of FIGO stage I-IIA patients

2009 · J. Herrstedt, J. Huober, et al. · Journal of Clinical Oncology · 8

Nachsorge und Hormonsubstitution nach Ovarialkarzinom

2002 · A. Stähle, G. Emons, et al. · Der Onkologe · 4

A randomized, phase III study (AGO-OVAR-9, GINECO-TCG, NSGO-OC-0102): Gemcitabine-paclitaxel-carboplatin (TCG) versus paclitaxel-carboplatin (TC) as first-line treatment of ovarian cancer (OC): Survival of FIGO stage I-IIA patients

2009 · J. Herrstedt, J. Huober, et al. · Journal of Clinical Oncology · 3

38 Influence of amifostine on neuroprotection in 1st-line treatment of advanced ovarian cancer with carboplatin/taxane-based chemotherapy - a double-blind, placebo-controlled, randomized phase II-study from the AGO Ovarian Cancer Study Group

2003 · P. Wimberger, R. Kimmig, et al. · European Journal of Cancer Supplements · 2

Nachsorge inklusive Hormonsubstitutionstherapie

2001 · A. Stähle, H. Kühnle, et al. · Der Gynäkologe · 2

Paclitaxel-carboplatin-gemcitabine (TCG) versus paclitaxel-carboplatin (TC) as first line treatment in women with ovarian cancer: A randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102)

2006 · AK Stähle, C Jackisch, et al. · Geburtshilfe und Frauenheilkunde · 1

Homograft—the optimal aortic valve substitute?

2000 · A Ståhle · European Heart Journal · 1

PACLITAXEL/CARBOPLATIN (TC) vs. PACLITAXEL/CARBOPLATIN gefolgt von TOPOTECAN (TOP) in der Therapie des fortgeschrittenen Ovarialkarzinoms.

2006 · HJ Lück, A Du Bois, et al. · Geburtshilfe und Frauenheilkunde

359 Neuroprotection With Amifostine in The 1St-Line Treatment of Advanced Ovarian Cancer With Carboplatin/Taxane-Based Chemotherapy – A Double-Blind, Placebo-Controlled, Randomized Phase Ii-Study From The Ago Ovarian Cancer Study Group

2004 · A.K. Belau, F. Hilpert, et al. · International Journal of Gynecological Cancer

172 Phase I/II study of PLD and carboplatin in patients with advanced gynaecological carcinomas. An interim analysis of the GYN II trial of the AGO ovarian cancer study group

2003 · V. Heilmann, A. Burges, et al. · European Journal of Cancer Supplements

164 Primary therapy of ovarian cancer with paclitaxel/carboplatin/gemcitabine (TCG): a phase II study (ovar-8 protocol)

2003 · A.K. Belau, U. Wagner, et al. · European Journal of Cancer Supplements

Works count: 17

Citation count: 343

H-index: 7

I10-index: 6